Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Salzmann

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Cancers|June 24, 2020
The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX InstrumentsTheresa Steeb, Anja Wessely, Konstantin Drexler, et al.
Cancers|October 21, 2020
Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma PatientsMartin Salzmann, Karolina Benesova, Kristina Buder-Bakhaya, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter studyMartin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Cancers|March 11, 2023
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective StudyMartin Salzmann, Alexander Wald, Henner Stege, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Trials|April 21, 2021
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trialPia Grabbe, Kathrin M Gschwendtner, Imad Maatouk, et al.
Oncoimmunology|April 28, 2022
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)Jessica C Hassel, Timo E Schank, Heiko Smetak, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Cancers|June 24, 2020
The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX InstrumentsTheresa Steeb, Anja Wessely, Konstantin Drexler, et al.
Cancers|October 21, 2020
Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma PatientsMartin Salzmann, Karolina Benesova, Kristina Buder-Bakhaya, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter studyMartin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Cancers|March 11, 2023
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective StudyMartin Salzmann, Alexander Wald, Henner Stege, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Trials|April 21, 2021
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trialPia Grabbe, Kathrin M Gschwendtner, Imad Maatouk, et al.
Oncoimmunology|April 28, 2022
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)Jessica C Hassel, Timo E Schank, Heiko Smetak, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Pageof 10